We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.55%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$899M
AUM Growth
+$163M
Cap. Flow
+$26.4M
Cap. Flow %
2.93%
Top 10 Hldgs %
55.22%
Holding
69
New
9
Increased
12
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$23M
2
IBB icon
iShares Biotechnology ETF
IBB
+$16.5M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.1M
4
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$6.7M
5
AGN
Allergan Inc
AGN
+$6.6M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$16.4M
2
PBYI icon
Puma Biotechnology
PBYI
+$13.6M
3
IMGN
Immunogen Inc
IMGN
+$6.53M
4
MDVN
MEDIVATION, INC.
MDVN
+$6.52M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 84.05%
2 Financials 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$163B
$94.6M 10.52%
1,504,712
– –
REGN icon
2
Regeneron Pharmaceuticals
REGN
$77.4B
$81.6M 9.08%
260,699
-19,060
-7% -$5.01M
CELG
3
DELISTED
Celgene Corp
CELG
$78.5M 8.74%
1,020,092
– –
BIIB icon
4
Biogen
BIIB
$30.7B
$46.2M 5.14%
191,983
– –
AMGN icon
5
Amgen
AMGN
$209B
$46.1M 5.13%
412,143
+212,000
+106% +$23M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$43.1M 4.8%
371,329
– –
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$122B
$37.9M 4.22%
499,764
+45,600
+10% +$3.63M
PRGO icon
8
Perrigo
PRGO
$1.43B
$25M 2.78%
202,607
– –
PBYI icon
9
Puma Biotechnology
PBYI
$402M
$24.6M 2.74%
458,816
-252,984
-36% -$13.6M
VTRS icon
10
Viatris
VTRS
$20.7B
$18.6M 2.07%
488,209
– –
SHPG
11
DELISTED
Shire pic
SHPG
$18.5M 2.06%
154,153
– –
AKRX
12
DELISTED
Akorn Inc
AKRX
$18.4M 2.05%
935,758
– –
IBB icon
13
iShares Biotechnology ETF
IBB
$9.52B
$17.6M 1.96%
+251,820
New +$16.5M
WCRX
14
DELISTED
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
$16.3M 1.81%
713,797
-69,000
-9% -$1.46M
INCY icon
15
Incyte
INCY
$24.9B
$16.1M 1.79%
421,300
– –
AET
16
DELISTED
Aetna Inc
AET
$15.8M 1.76%
246,841
+49,600
+25% +$3.18M
ONXX
17
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$15.5M 1.72%
124,238
-129,618
-51% -$16.4M
AGN
18
DELISTED
Allergan Inc
AGN
$15.1M 1.68%
166,577
+73,500
+79% +$6.6M
CBST
19
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$14.4M 1.6%
226,772
-39,200
-15% -$2.37M
MRK icon
20
Merck
MRK
$321B
$14.1M 1.57%
310,858
– –
TEVA icon
21
Teva Pharmaceuticals
TEVA
$41.2B
$13.4M 1.49%
354,476
+43,000
+14% +$1.68M
AGN
22
DELISTED
Allergan plc
AGN
$13.2M 1.47%
91,500
– –
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.7B
$13.1M 1.46%
181,870
+106,870
+142% +$7.1M
HOLX
24
DELISTED
Hologic
HOLX
$12.2M 1.36%
592,915
– –
ALR
25
DELISTED
Alere Inc
ALR
$11.3M 1.26%
369,553
+53,000
+17% +$1.61M
1
2 3

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, Tekla Capital Management held 69 positions worth $899M, up 22% from $735M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Tekla Capital Management's Q3 2013 filing shows 9 new, 12 increased, 10 reduced and 6 closed positions. Its largest new stake was iShares Biotechnology ETF: 251,820 shares worth $17.6M. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $16.4M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 84% a quarter earlier, followed by Financials.

  • Tekla Capital Management's largest Q3 2013 buy was iShares Biotechnology ETF: 251,820 shares worth $17.6M.
  • Tekla Capital Management added most to Amgen in Q3 2013, an estimated $23M increase.
  • Tekla Capital Management's biggest Q3 2013 reduction was ONYX PHARMACEUTICALS INC, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Immunogen Inc in Q3 2013, selling an estimated $6.53M.
  • Tekla Capital Management's ten largest holdings make up 55% of its $899M portfolio in Q3 2013.
  • Tekla Capital Management opened 9 new positions and closed 6 in Q3 2013.
  • Tekla Capital Management's portfolio value rose 22% quarter-over-quarter to $899M.

Based on Tekla Capital Management's 13F filing for Q3 2013, filed 30 Oct 2013.